Skip to main content
Caplight Logo









Arpelos Biosciences

Arpelos Biosciences

Private
Cambridge, MassachusettsHealthcare & Life Scienceshttps://www.arpelos.com/

Last Round

Seed

Mar 15, 2024

Total Funding Raised

$9.6M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Arpelos Biosciences is a biotechnology company that develops multivalent medicines to achieve unprecedented potency and selectivity.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Medical AI

Business Model

B2B

Customer Profile

Revenue Share, Government Contracts

AI Layer

Non-AI

Keywords

multivalent medicinesmultispecific biologicstargeted therapeuticsprotein engineeringdrug discoverybiopharmacomputational drug discoveryimmunologybiologicsprecision medicinetherapeutics developmentpre-clinical therapeutics

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Arpelos Biosciences Comparables

Compare Arpelos Biosciences with similar companies based on industry and business-model similarity.

Arpelos Biosciences comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Synthetic Design Lab
84%
Valink Therapeutics
82%
AI Proteins
76%

Arpelos Biosciences Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedMar 15, 2024

Arpelos Biosciences Investors

Notable investors and investment history

Arpelos Biosciences investors
InvestorRounds
Lux CapitalSeed
General CatalystSeed
Pillar VCSeed
82VSSeed
Wing Venture CapitalSeed
8VCSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 29, 2026

    Monthly visitors increased 32% MoM.

  • Jun 18, 2026

    Monthly visitors grew 42% MoM.

Arpelos Biosciences Filings

Explore SEC and related filing metadata, where available.

Arpelos Biosciences filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Arpelos Biosciences's valuation, stock price, and market status.

Is Arpelos Biosciences a public or private company?

Arpelos Biosciences is a private company.

What is the current stock price of Arpelos Biosciences?

Arpelos Biosciences is a private company with no public stock price. No recent secondary market data is available.

How much is Arpelos Biosciences worth (valuation)?

Valuation information for Arpelos Biosciences is not publicly available.

Can I buy Arpelos Biosciences stock?

Arpelos Biosciences shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Arpelos Biosciences's last funding round?

Arpelos Biosciences's most recent funding round was Seed on March 15, 2024.

Who are the main investors in Arpelos Biosciences?

Key investors in Arpelos Biosciences include Lux Capital, General Catalyst, Pillar VC, 82VS, Wing Venture Capital.

Will Arpelos Biosciences IPO soon?

No public IPO plans have been announced for Arpelos Biosciences.

How can I track Arpelos Biosciences secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Arpelos Biosciences's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersCambridge, Massachusetts
Employee Range8
Year Founded2024
Last FundingMar 15, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?